Structural and functional characterization of two alpha-synuclein strains

Nature Communications

Volumn 4, Issue , 2013, Pages

  Bousset, Luc ^a   Pieri, Laura ^a   Ruiz Arlandis, Gemma ^a   Gath, Julia ^b   Jensen, Poul Henning ^c   Habenstein, Birgit ^d   Madiona, Karine ^a   Olieric, Vincent ^e   Böckmann, Anja ^d   Meier, Beat H ^b   Melki, Ronald ^a  

^a LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

^b ETH ZURICH   (Switzerland)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITÉ LYON 1   (France)

^e PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AGGREGATION; CYTOLOGY; NERVOUS SYSTEM DISORDER; PHENOTYPE; PROTEIN; TOXICITY;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRAIN DIFFERENCE; TOXICITY;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CELL SURVIVAL; ESCHERICHIA COLI; HUMANS; NEURONS; PROTEIN FOLDING; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SCATTERING, SMALL ANGLE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84892150877     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3575     Document Type: Article

References (51)

1. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 Suppl, S10-7 (2004).
2. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501 (2001).
3. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
4. Lee, H. J., Choi, C. & Lee, S. J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678 (2002).
5. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G. & Goedert, M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294 (1998).
6. Uversky, V. N. & Eliezer, D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr. Protein Pept. Sci. 10, 483-499 (2009).
7. Goldberg, M. S. & Lansbury, Jr. P. T. Is there a cause-and effect relationship between alpha-synuclein fibrilization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119 (2000).
8. Caughey, B. & Lansbury, Jr P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
9. Winner, B. et al. in vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194-4199 (2011).
10. Danzer, K. M. et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220-9232 (2007).
11. Pieri, L., Madiona, K., Bousset, L. & Melki, R. Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894-2905 (2012).
12. Prusiner, S. B. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513 (2012).
13. Brundin, P., Melki, R. & Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301-307 (2010).
14. Aguzzi, A. & Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64, 783-790 (2009).
15. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320 (1998).
16. Wood, S. J. et al. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512 (1999).
17. Uversky, V. N., Li, J. & Fink, A. L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737-10744 (2001).
18. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to- neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010-13015 (2009).
19. Hansen, C. et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725 (2011).
20. Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinsonlike neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
21. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008).
22. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008).
23. Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225-2228 (2012).
24. Luk, K. C. et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975-986 (2012).
25. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
26. Bruce, M., Fraser, H., McBride, P., Scott, J. & Dickinson, A. The basis of strain variation in scrapie. In Prion Diseases of Humans and Animals 497-508, 1992).
27. Ohhashi, Y., Ito, K., Toyama, B. H., Weissman, J. S. & Tanaka, M. Differences in prion strain conformations result from non-native interactions in a nucleus. Nat. Chem. Biol. 6, 225-230 (2010).
28. Tanaka, M., Collins, S. R., Toyama, B. H. & Weissman, J. S. The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589 (2006).
29. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262-265 (2005).
30. van Raaij, M. E., Segers-Nolten, I. M. & Subramaniam, V. Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys. J. 91, L96-L98 (2006).
31. Hoyer, W. et al. Dependence of alpha-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383-393 (2002).
32. Paleologou, K. E. et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093-1101 (2009).
33. Heise, H. et al. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc. Natl Acad. Sci. USA 102, 15871-15876 (2005).
34. Gath, J. et al. Solid-state NMR sequential assignments of alpha-synuclein. Biomol. NMR Assign. 6, 51-55 (2012).
35. Gath, J. et al. Solid-state NMR sequential assignments of a new polymorph of α-synuclein. Biomol. NMR Assign. in press.
36. Lv, G. et al. Structural comparison of mouse and human alpha-synuclein amyloid fibrils by solid-state NMR. J. Mol. Biol. 420, 99-111 (2012).
37. Karpinar, D. P. et al. Pre-fibrillar alpha-synuclein variants with impaired betastructure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256-3268 (2009).
38. Comellas, G., Lemkau, L. R., Zhou, D. H., George, J. M. & Rienstra, C. M. Structural intermediates during alpha-synuclein fibrillogenesis on phospholipid vesicles. J. Am. Chem. Soc. 134, 5090-5099 (2012).
39. Cornilescu, G., Delaglio, F. & Bax, A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 13, 289-302 (1999).
40. Der-Sarkissian, A., Jao, C. C., Chen, J. & Langen, R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278, 37530-37535 (2003).
41. Chen, M., Margittai, M., Chen, J. & Langen, R. Investigation of alpha-synuclein fibril structure by site-directed spin labelling. J. Biol. Chem. 282, 24970-24979 (2007).
42. Miake, H., Mizusawa, H., Iwatsubo, T. & Hasegawa, M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277, 19213-19219 (2002).
43. Freundt, E. C. et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann. Neurol. 72, 517-524 (2012).
44. Uversky, V. N. A protein-chameleon: conformational plasticity of alphasynuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211-234 (2003).
45. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134 (2004).
46. Ghee, M., Melki, R., Michot, N. & Mallet, J. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly. FEBS J. 272, 4023-4033 (2005).
47. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606-1619 (2000).
48. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J. & Schubert, D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys. J. 82, 1096-1111 (2002).
49. Seshadri, S., Khurana, R. & Fink, A. L. Fourier transform infrared spectroscopy in analysis of protein deposits. Methods. Enzymol. 309, 559-576 (1999).
50. Schägger, H. & Von Jagow, G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal. Biochem. 166, 368-379 (1987).
51. Reutelingsperger, C. P. & van Heerde, W. L. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol. Life Sci. 53, 527-532 (1997).